giredestrant investigational
Selected indexed studies
- Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. (Clin Cancer Res, 2024) [PMID:37921755]
- ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER(+) breast cancer. (Nat Cancer, 2025) [PMID:39805955]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer. (2024) pubmed
- ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER(+) breast cancer. (2025) pubmed